News

30th September 2019

Quay Pharma partnering this years Microbiome Movement – Drug Development & Nutrition Asia Summit

Quay Pharma is an independent, privately-owned Contract Development Manufacturing Organisation (CDMO). They specialise in the development of innovative new entities for biotech companies, globally. They are proud to be attending and partnering this years event.

Part of the globally recognised Microbiome Movement, the 2nd Microbiome Movement – Drug Development & Nutrition Asia Summit will return to help translational microbiome researchers in APAC discover, develop and deliver the future generation of microbiome-based products across therapeutic and nutritional industry applications.

Join and interact with industry and academic key opinion leaders from Asia’s prominent microbiome-focused organisations to accelerate your knowledge of the field, overcome key challenges in translating your microbiome research to commercial reality and help deliver a new future for healthcare.

Quay Pharma is experienced in providing a comprehensive out-sourcing service for formulation and analytical development with subsequent clinical trials manufacturing for pharmaceutical and biotechnology companies worldwide.
Working as a dedicated, pro-active part of your team we apply strong project management and technical expertise to take products quickly and cost effectively from late stage pre-clinical through to the end of phase II clinical trials.
Quay Pharma has built a reputation for specialising in the formulation of APIs that exhibit poor solubility and bio-availability and those which require modified or controlled release.
Ryan Wilson, Head of Live Bio Programmes at Quay Pharma will be speaking on Day One of the conference (12.30, 17th Sept 2019) on Development of Oral Live Biotherapeutics – a CDMO Perspective.
View Quay Pharma’s member profile here: https://www.mediwales.com/members/quay-pharma/